Board of Directors
Dr. Thiel has served as a member of our board of directors since September 2018. Dr. Thiel brings over 25 years of global biopharmaceutical industry experience, including successfully leading teams responsible for the initial launch and commercialization of hematology/oncology medicines. He currently serves as Chief Executive Officer of Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies. Prior to joining Abeona, Dr. Thiel was Executive Vice President and Chief Commercial Officer of Alexion Pharmaceuticals, Inc., a leading global biopharmaceutical company focused on serving patients affected by rare diseases. While at Alexion, he led one of the most successful enzyme replacement commercial launches in history. Before leading the overall commercial organization at Alexion, he served as its Senior Vice President, Europe/Middle East/Africa and Asia Pacific where he was responsible for driving Alexion’s global commercial operations in these regions, which included guiding the launch of Strensiq® and Kanuma® in new metabolic indications. Prior to joining Alexion, Dr. Thiel was Vice President, Head of Europe at Amgen. In this role, he led regional operations for over 4,500 employees and was responsible for multiple products in hematology/oncology, nephrology, and bone disorders, as well as prepared for new product launches in inflammation and cardiology. He also held various other senior leadership positions at Amgen, including General Manager, Germany, and General Manager, Central and Eastern Europe, where he expanded the company’s presence into four new markets. He also served as Head of the Oncology franchise in Europe during the time of several blockbuster product launches. Prior to Amgen, Dr. Thiel held several sales and marketing leadership roles across Europe at Roche.
Dr. Thiel conducted his doctorate in molecular biology and biochemistry at Max Planck Institute for Biophysical Chemistry in Goettingen, Germany.